FDA to Review Bristol Myers Opdivo/Yervoy Combo in Liver Cancer
By Colin Kellaher
Bristol Myers Squibb on Wednesday said the Food and Drug Administration has accepted its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the early treatment of certain patients with the most common form of liver cancer.
The Princeton, N.J., drugmaker said the application covers the combination as a potential first-line treatment for adults with unresectable hepatocellular carcinoma.
The FDA has set a target action date of April 21, 2025, for the application.
Hepatocellular carcinoma, which accounts for up to 85% of all liver cancers, is often diagnosed in an advanced stage, where effective treatment options are limited and are usually associated with poor outcomes.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 21, 2024 07:45 ET (11:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now
United States